← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Aquinnah Pharmaceuticals, Inc.
Newton, MA
$10,492,863
Total funding
5
Grants
Funding over time
peak $2.5M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,492,863 · 5
By mechanism
R44$9,431,105 · 3
R43$1,061,758 · 2
Investigators at Aquinnah Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
TDP-43 aggregation inhibitors for the treatment of ALS$2,510,981
R44 · FY2019 · NS
Development of a novel oral brain penetrant therapeutic for ALS disease$1,499,212
R44 · FY2025 · NS
Targeting tau for the development of novel Alzheimer's disease therapeutics$1,475,961
R44 · FY2020 · AG
Targeting tau for the development of novel Alzheimer's disease therapeutics$1,022,579
R44 · FY2021 · AG
Development of a novel Alzheimer's disease therapeutic targeting tau$999,721
R44 · FY2024 · AG
Development of a novel Alzheimer's disease therapeutic targeting tau$998,691
R44 · FY2025 · AG
TDP-43 aggregation inhibitors for the treatment of ALS$923,960
R44 · FY2018 · NS
TDP-43 aggregation inhibitors for the treatment of ALS$499,556
R43 · FY2015 · NS
Tau/TIA1 aggregation inhibitors for the treatment of AD$379,465
R43 · FY2018 · AG
TDP-43 aggregation inhibitors for the treatment of ALS$182,737
R43 · FY2016 · NS